Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries

American Journal of Tropical Medicine and Hygiene

Volumn 65, Issue 6, 2001, Pages 810-821

  Grant, A D ^a   Kaplan, J E ^a   De Cock, K M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FANSIDAR; FLUCONAZOLE; ISONIAZID; PNEUMOCOCCUS VACCINE; PYRAZINAMIDE; RIFAMPICIN;

AFRICA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; DRUG EFFECT; DRUG EFFICACY; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFLUENZA; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT CARE; SCREENING TEST; STREPTOCOCCUS INFECTION; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; STREPTOCOCCUS;

EID: 0035681022     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.810     Document Type: Article

References (72)

1. Profound immunosuppression across the spectrum of opportunistic disease among hospitalised HIV-infected adults in Abidjan, Côte d'Ivoire
2. Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: Association between clinical stages and laboratory markers
3. Preventing opportunistic infections in human immunodeficiency virus-infected persons: Implications for the developing world
4. The growing challenge of HIV/AIDS in developing countries
5. The changing pattern of transmission and clinical presentation of HIV infection in the Western Cape region of South Africa (1984-1995)
6. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya
7. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi
8. Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire
9. Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania
10. A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda
11. Pathogens and predictors of fatal septicemia associated with human immunodeficiency virus infection in Ivory Coast, West Africa
12. Cryptococcosis, another growing burden for central Africa
13. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe
14. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV1) natural history cohort in Uganda
15. The mortality and pathology of HIV infection in a West African city
16. Changing patterns of mortality across Europe in patients infected with HIV-1
17. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
18. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial
19. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
20. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis
21. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
22. Effect of preventive treatment for tuberculosis in adults infected with HIV: Systematic review of randomised placebo controlled trials
23. Isoniazid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomized controlled trials
24. Tuberculosis preventive therapy in HIV-infected persons: Feasibility issues in developing countries
25. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial
26. Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy
27. Targeted tuberculin testing and treatment of latent tuberculosis infection
28. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection
29. Tuberculosis control and molecular epidemiology in a South African gold-mining community
30. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
31. Preventive therapy for tuberculosis in HIV infection: The promise and the reality
32. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counselling and testing centre
33. Global surveillance for antituberculous drug resistance 1994-1997
34. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: The example of Zambia
35. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients - A least-cost analysis
36. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months
37. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: A controlled clinical trial
38. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: A randomised trial
39. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection
40. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine
41. Natural history and spectrum of disease in adults with HIV/AIDS in Africa
42. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: A randomised controlled trial
43. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: A randomised trial
44. Cutaneous reactions to trimethoprim-sulfamethoxazole in African patients with the acquired immunodeficiency syndrome
45. Cotrimoxazole in HIV-1 infection
46. Susceptibilities to co-trimoxazole of pathogens isolated from blood and stool specimens in Abidjan, Ivory Coast, 1994-1996
47. Multi-drug resistant non-typhi salmonellae in Kenya
48. Co-trimoxazole in HIV-1 infection
49. Salmonella serogroups identified from adult diarrhoeal out-patients in Addis Ababa, Ethiopia: Antibiotic resistance and plasmid profile analysis
50. Antibiotic resistance of prevalent Salmonella and Shigella strains in northwest Ethiopia
51. Aetiology, outcome and risk factors for mortality among adults with acute pneumonia in Kenya
52. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults
53. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era
54. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides
55. Prevention of pneumococcal pneumonia by vaccination
56. Antibiotic resistance in Streptococcus pneumoniae
57. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya
58. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
59. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
60. Pneumonia in HIV-infected patients: A case-control survey of factors involved in risk and prevention
61. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
62. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial
63. Pneumococcal vaccination in HIV-1-infected adults in Uganda: Humoral response and two vaccine failures
64. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
65. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
66. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
67. Global trade and access to medicines: AIDS treatments in Thailand
68. Acquired immunodeficiency syndrome (AIDS): Interim proposal for a WHO staging system for HIV infection and disease
69. Primary prevention with cotrimoxazole for HIV-1-infected adults: Results of the pilot study in Dakar, Senegal
70. Initiating cotrimoxazole prophylaxis in HIV-infected patients in Africa: An evaluation of the provisional WHO/UNAIDS recommendations